Intellectual Property
(Non-confidential)

City of Hope
NATIONAL MEDICAL CENTER AND
BECKMAN RESEARCH INSTITUTE

DNA Test Linked to KRAS Predicts Survival in Cancer Patients



DESCRIPTION

Non-small-cell lung cancer (NSCLC), accounts for about 85% of all lung cancers and is the leading cause of cancer deaths worldwide. Despite advances in early detection and surgical resection, NSCLC often has a high recurrence. *KRAS* is an oncogene located on Chromosome 12 that encodes a protein called K-Ras that is involved in regulating cell division and is downstream of epidermal growth factor receptor (EGFR). This COH technology covers the analysis of the KRAS gene region for specific deletions and the application of this information to predict survival in NSCLC patients. By leveraging this information clinicians can better tailor how aggressively a patent is treated.

KEY ASPECTS

- Novel diagnostic tool for prediction of survival in lung cancer patients
- Detection techniques include: robust dosage-polymerase chain reaction (RD-PCR), fluorescent *in situ* hybridization (FISH), and comparative genomic hybridization (CGH).

INTELLECTUAL PROPERTY

Title	US Application Number	Filed
Methods for Predicting Survival in Cancer Patients	61/314,511	3/16/2010

CONTACT

Matthew Grunseth, M.B.S.
Manager, Office of Technology Licensing
Telephone: (626) 471-7221 | Email: mgrunseth@coh.org

This material is a summary of public domain and non-confidential City of Hope information. Additional material may be disclosed under a confidentiality agreement.